Roles and Responsibilities:
- Provide strategic Patient Safety input to drug development and post-marketing programs of the given product.
- Compile safety information for clinical overviews, post-marketing safety assessment, risk management plans, labeling justifications, CCSI development and written summaries of clinical safety of common technical documents.
- Undertake and prepare high-quality evaluation documents to describe safety findings in collaboration with external vendors (when applicable).
- Leads and reviews PV aggregate safety reports for assigned product(s) (e.g., DSUR, PBRER/PSUR), including safety database requests, working with the report's authors, and ensuring effective planning in accordance with the regulatory timelines.
- Responsible for preparation and maintenance of core safety information as used for Investigator's brochures and labeling.
- Lead the signal detection activities including safety surveillance activities, medical review and benefit-risk assessment of assigned product(s).
- Support the development of risk management strategies for investigational compounds.
- Address safety questions from Regulatory Authorities.
- Chair the multidisciplinary Safety Management Team whose responsibilities include safety surveillance (signal detection and evaluation), risk management planning, and making recommendations related to safety issues.
- Provide leadership to support project discussions with governance boards, including interactions with Medical Safety Review Council and leads the safety strategy for regulatory communication.
- Provide regular updates on safety data trending, signaling and other safety related issues to the Medical Safety Review Council (MSRC) and recommend pharmacovigilance / risk management actions on behalf of the Medical Safety Team.
- Support PV audits and inspections by participating in audit readiness activities and serving as subject matter expert during regulatory inspections.
Qualifications:
- A Medical degree with clinical experience is required.
- Must have 7+ years of profound experience in Drug Safety & Pharmacovigilance and Risk Management in pharmaceutical companies in both clinical and post-marketing. Experience in non-clinical is desirable.
- Experience in rare diseases and neurology preferred.
- Experience in signal detection with demonstrated experience in analysis, and interpretation of medical and scientific data.
- Experience in safety data analysis and writing product-related aggregate reports and safety assessments.
- Experience in the design, implementation, tracking and follow up of risk management plans.
- Experience in MedDRA coding and search strategies.
- Knowledge of regulations and guidance (EU, US and global).
- Direct experience in interacting with Health Authorities preferred.
- New product launch experience desired.
Skills:
- Ability to apply clinical judgment to interpret case information.
- Ability to synthesize large amounts of medical data and draw medical conclusions.
- Excellent interpersonal and communication skills (both written and oral) required.
- Demonstrated ability to work effectively in a cross-functional team environment (including Safety, Clinical Development, Medical Affairs, Clinical Operations, and Regulatory), as well as independently.
- Attention to detail and the ability to work individually, within a multi-disciplinary team, as well as with external partners and vendors.
- Strong knowledge of international regulatory requirements including ICH, European Pharmacovigilance legislation, FDA and CIOMS.
- Project management skills preferred.
Similar Jobs
What We Do
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.







